Hospital
Sharp Memorial Hospital
Sharp Memorial Hospital was paid $133.75M by Medicaid between Jan 2018 and Dec 2024, across 306 billing codes. Its largest line is 99283, emergency room visit (moderate) — 17% of everything it billed.
33Billing provider infoSHARP MEMORIAL HOSPITAL
SAN DIEGO, CA 92123
SAN DIEGO, CA 92123
33aNPI1407839921assigned 11/29/2005
33bProvider typeWomen's Hospital
28Total paid$133.75M
24GClaims1,447,137
24DCodes billed306
24AFirst – last monthJan 2018 – Dec 2024
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 247,962 | $18.22M | |
| 2019 | 239,144 | $18.79M | |
| 2020 | 178,321 | $15.81M | |
| 2021 | 214,167 | $18.97M | |
| 2022 | 226,955 | $22.80M | |
| 2023 | 222,501 | $24.54M | |
| 2024incomplete | 118,087 | $14.61M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 17% | 46,355 | 42,671 | $23.08M |
| 0450 | Emergency room services | 16% | 63,029 | 56,427 | $21.13M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 8.2% | 15,019 | 14,589 | $10.95M |
| 99499 | 5.5% | 22,202 | 18,039 | $7.30M | |
| 80053 | Comprehensive metabolic panel | 3.6% | 117,648 | 105,066 | $4.84M |
| 70450 | Computed tomography, head or brain; without contrast material | 3.3% | 17,389 | 16,714 | $4.39M |
| 99199 | Unlisted special service, procedure or report | 3.2% | 5,182 | 4,231 | $4.23M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.7% | 8,491 | 7,635 | $3.57M |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.3% | 53,162 | 48,241 | $3.06M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 2.3% | 11,197 | 10,113 | $3.06M |
| 0360 | 1.7% | 2,610 | 1,609 | $2.25M | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.7% | 120,165 | 106,415 | $2.22M |
294 more codes
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.6% | 27,141 | $2.08M |
| 71045 | Radiologic examination, chest; single view | 1.5% | 45,338 | $2.05M |
| 72125 | Computed tomography, cervical spine; without contrast material | 1.5% | 7,037 | $2.04M |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.5% | 19,786 | $2.02M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.4% | 4,585 | $1.83M |
| 59025 | Fetal non-stress test | 1.3% | 12,038 | $1.69M |
| 0762 | 1.2% | 3,497 | $1.60M | |
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.1% | 3,134 | $1.46M |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | 1.0% | 11,982 | $1.34M |
| 83735 | <1% | 63,526 | $1.08M | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 2,648 | $1.07M |
| 84484 | <1% | 32,416 | $874K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 17,217 | $846K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 11,239 | $836K |
| 83690 | <1% | 37,713 | $816K | |
| 84702 | <1% | 23,781 | $769K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 4,264 | $693K |
| 70498 | <1% | 1,236 | $672K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 2,066 | $659K |
| Z7502 | <1% | 17,983 | $644K | |
| 70486 | <1% | 1,858 | $578K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 5,588 | $565K |
| 76801 | <1% | 3,507 | $559K | |
| 81001 | <1% | 40,901 | $539K | |
| 85610 | <1% | 34,145 | $517K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 4,697 | $503K |
| 76830 | Ultrasound, transvaginal | <1% | 3,772 | $490K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 11,482 | $453K |
| 87040 | <1% | 5,738 | $453K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 12,096 | $436K |
| 97799 | <1% | 9,082 | $403K | |
| 0721 | <1% | 6,173 | $374K | |
| 82962 | <1% | 22,566 | $374K | |
| 93971 | <1% | 2,254 | $367K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 3,974 | $365K |
| 0710 | <1% | 2,334 | $311K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 2,482 | $295K |
| 71250 | <1% | 1,363 | $278K | |
| 0300 | <1% | 260 | $263K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 11,718 | $262K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 7,046 | $258K |
| 97139 | <1% | 7,031 | $244K | |
| 0160 | <1% | 247 | $224K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 4,672 | $223K |
| 93970 | <1% | 1,031 | $209K | |
| 82077 | <1% | 5,715 | $203K | |
| 0250 | <1% | 2,926 | $201K | |
| 73030 | <1% | 3,010 | $195K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 3,469 | $183K |
| 84703 | <1% | 13,287 | $179K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 570 | $177K |
| 73562 | <1% | 3,108 | $168K | |
| 72100 | <1% | 2,510 | $165K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 6,871 | $159K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 3,350 | $158K |
| 80047 | <1% | 5,094 | $157K | |
| 0206 | <1% | 18 | $150K | |
| 86900 | <1% | 5,884 | $149K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 1,252 | $148K |
| 93017 | <1% | 975 | $148K | |
| 85379 | <1% | 5,706 | $147K | |
| Z9725 | <1% | 3,408 | $146K | |
| 86832 | <1% | 2,441 | $146K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 5,270 | $142K |
| 73630 | <1% | 2,143 | $130K | |
| 0760 | <1% | 542 | $128K | |
| 73610 | <1% | 2,032 | $126K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,273 | $126K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 168 | $120K |
| 83880 | <1% | 5,400 | $118K | |
| 86833 | <1% | 2,445 | $116K | |
| 86901 | <1% | 5,873 | $115K | |
| 86828 | <1% | 1,597 | $114K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 4,109 | $103K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 6,306 | $102K |
| 85730 | <1% | 7,691 | $95K | |
| 73130 | <1% | 1,573 | $93K | |
| 83605 | <1% | 6,560 | $92K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 6,017 | $92K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 254 | $91K |
| 96112 | <1% | 585 | $90K | |
| 81003 | <1% | 10,490 | $90K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 4,335 | $88K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 249 | $87K |
| 80143 | <1% | 2,273 | $86K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 2,575 | $85K |
| 76770 | <1% | 944 | $84K | |
| 82550 | <1% | 5,001 | $82K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,285 | $77K |
| 96376 | <1% | 2,336 | $77K | |
| J3490 | Unclassified drugs | <1% | 1,576 | $77K |
| 0761 | <1% | 2,414 | $76K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,044 | $75K |
| G0378 | Hospital observation service, per hour | <1% | 629 | $75K |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 99 | $74K |
| 80179 | <1% | 2,030 | $74K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 2,515 | $73K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 500 | $72K |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 271 | $65K |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 2,021 | $64K |
| 72131 | <1% | 302 | $63K | |
| 0258 | <1% | 4,128 | $61K | |
| 72170 | <1% | 927 | $58K | |
| 70491 | <1% | 134 | $56K | |
| 73502 | <1% | 1,241 | $52K | |
| 86977 | <1% | 1,362 | $49K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 16,597 | $47K |
| 73110 | <1% | 777 | $47K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 2,047 | $46K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,792 | $46K |
| 76642 | <1% | 820 | $45K | |
| 97161 | <1% | 951 | $45K | |
| 85027 | <1% | 3,535 | $44K | |
| 82553 | <1% | 1,710 | $44K | |
| 84145 | <1% | 2,420 | $42K | |
| 70496 | <1% | 74 | $41K | |
| 87081 | <1% | 1,856 | $41K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 820 | $40K |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 529 | $40K |
| 85014 | <1% | 4,984 | $40K | |
| 87186 | <1% | 3,802 | $38K | |
| 87510 | <1% | 2,210 | $37K | |
| 90715 | <1% | 1,947 | $37K | |
| 87480 | <1% | 2,218 | $37K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 3,081 | $36K |
| 87660 | <1% | 2,220 | $36K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 2,291 | $36K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 8,953 | $36K |
| 72040 | <1% | 532 | $35K | |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 216 | $34K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 117 | $33K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 12,874 | $31K |
| 73080 | <1% | 491 | $31K | |
| 87077 | <1% | 4,211 | $30K | |
| 86830 | <1% | 1,312 | $29K | |
| 82803 | <1% | 1,148 | $27K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 899 | $27K |
| 84439 | <1% | 3,092 | $26K | |
| 86850 | <1% | 1,257 | $26K | |
| 94799 | <1% | 957 | $26K | |
| 97116 | <1% | 1,584 | $26K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 596 | $25K |
| 74174 | <1% | 27 | $25K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 5,861 | $25K |
| Z7500 | <1% | 710 | $24K | |
| 80061 | Lipid panel | <1% | 6,338 | $23K |
| 86140 | <1% | 2,206 | $22K | |
| 73590 | <1% | 475 | $22K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 342 | $22K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 66 | $22K |
| 77080 | <1% | 495 | $22K | |
| 86831 | <1% | 1,312 | $21K | |
| 97162 | <1% | 926 | $21K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 17,823 | $20K |
| 0324 | <1% | 219 | $20K | |
| 84550 | <1% | 6,380 | $20K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 51 | $19K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 420 | $19K |
| 87631 | <1% | 629 | $18K | |
| 96113 | <1% | 251 | $17K | |
| 84100 | <1% | 5,923 | $16K | |
| 76870 | <1% | 111 | $16K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 4,295 | $15K |
| 93976 | <1% | 87 | $15K | |
| 83615 | <1% | 1,770 | $15K | |
| 0270 | <1% | 304 | $15K | |
| 85652 | <1% | 2,085 | $15K | |
| 87641 | <1% | 989 | $14K | |
| 87070 | <1% | 1,228 | $14K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 467 | $14K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 3,765 | $14K |
| 0730 | <1% | 156 | $14K | |
| 0370 | <1% | 580 | $14K | |
| 77066 | Tomosynthesis, mammo | <1% | 284 | $14K |
| 80197 | <1% | 5,925 | $13K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 27 | $13K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,413 | $13K |
| 82330 | <1% | 1,125 | $12K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 98 | $12K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 6,334 | $11K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 3,187 | $10K |
| J2704 | Injection, propofol, 10 mg | <1% | 2,057 | $10K |
| 82570 | <1% | 2,257 | $9K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 562 | $9K |
| J1439 | Injection, ferric carboxymaltose, 1 mg | <1% | 13 | $9K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 2,735 | $8K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 4,925 | $8K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 203 | $8K |
| Q3014 | Telehealth originating site facility fee | <1% | 729 | $8K |
| 73560 | <1% | 201 | $7K | |
| 84132 | <1% | 842 | $7K | |
| 82248 | <1% | 671 | $6K | |
| 72128 | <1% | 26 | $6K | |
| M0222 | Intravenous injection, bebtelovimab, includes injection and post administration monitoring | <1% | 53 | $6K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 3,730 | $6K |
| 84295 | <1% | 770 | $6K | |
| 70487 | <1% | 12 | $6K | |
| 82728 | <1% | 892 | $6K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 352 | $5K |
| 87799 | <1% | 764 | $5K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 711 | $5K |
| 73140 | <1% | 109 | $5K | |
| 87205 | <1% | 1,113 | $5K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 2,090 | $5K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,876 | $4K |
| 0420 | <1% | 42 | $4K | |
| 88240 | <1% | 1,047 | $4K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 3,080 | $4K |
| 10060 | <1% | 54 | $4K | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 2,987 | $4K |
| V2632 | Posterior chamber intraocular lens | <1% | 220 | $4K |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 528 | $4K |
| 87497 | <1% | 526 | $4K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 852 | $3K |
| 83540 | <1% | 1,025 | $3K | |
| 93880 | <1% | 19 | $3K | |
| 82731 | <1% | 36 | $3K | |
| 86308 | <1% | 154 | $3K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 137 | $3K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 188 | $3K |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 1,367 | $3K |
| 97010 | <1% | 439 | $3K | |
| 73090 | <1% | 67 | $3K | |
| 77065 | Tomosynthesis, mammo | <1% | 78 | $3K |
| 71010 | <1% | 137 | $3K | |
| 83550 | <1% | 906 | $3K | |
| S0164 | Injection, pantoprazole sodium, 40 mg | <1% | 497 | $3K |
| 73620 | <1% | 58 | $3K | |
| 96367 | <1% | 59 | $3K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 1,122 | $3K |
| 97035 | <1% | 120 | $2K | |
| 77062 | <1% | 86 | $2K | |
| 0272 | <1% | 134 | $2K | |
| 29125 | <1% | 25 | $2K | |
| M0247 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring | <1% | 12 | $2K |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 211 | $2K |
| 83970 | <1% | 319 | $2K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 14 | $2K |
| 82140 | <1% | 132 | $1K | |
| 87449 | <1% | 167 | $1K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 448 | $1K |
| 97163 | <1% | 25 | $1K | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 109 | $1K |
| J3410 | Injection, hydroxyzine hcl, up to 25 mg | <1% | 57 | $1K |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 102 | $995.69 |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 12 | $990.00 |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 49 | $981.24 |
| 88304 | <1% | 49 | $941.28 | |
| 73120 | <1% | 28 | $918.42 | |
| 72072 | <1% | 13 | $917.81 | |
| 86780 | <1% | 125 | $857.97 | |
| 97166 | <1% | 30 | $828.40 | |
| 80074 | <1% | 13 | $816.09 | |
| 73660 | <1% | 13 | $803.47 | |
| 82607 | <1% | 240 | $801.25 | |
| 72192 | <1% | 12 | $753.26 | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 60 | $724.30 |
| 76536 | <1% | 12 | $721.42 | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 13 | $662.74 |
| 72070 | <1% | 15 | $635.74 | |
| 97165 | <1% | 15 | $619.48 | |
| 73552 | <1% | 12 | $494.00 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 45 | $458.63 |
| 87427 | <1% | 13 | $357.94 | |
| J1815 | Injection, insulin, per 5 units | <1% | 49 | $336.28 |
| 87075 | <1% | 40 | $288.46 | |
| 81015 | <1% | 30 | $248.61 | |
| 87045 | <1% | 13 | $232.49 | |
| 84153 | <1% | 24 | $226.73 | |
| 82043 | <1% | 246 | $220.87 | |
| 80164 | <1% | 19 | $213.06 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 69 | $206.31 |
| 80069 | <1% | 60 | $204.96 | |
| 82565 | <1% | 15 | $184.57 | |
| 90662 | <1% | 88 | $176.31 | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 31 | $163.22 |
| 87046 | <1% | 13 | $159.66 | |
| G2012 | Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m service provided within the previous 7 days nor leading to an e/m service or procedure within the next 24 hours or soonest available appointment; 5-10 minutes of medical discussion | <1% | 105 | $157.73 |
| V2630 | Anterior chamber intraocular lens | <1% | 13 | $151.55 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 41 | $140.82 |
| 82009 | <1% | 27 | $131.71 | |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 29 | $122.93 |
| 88342 | <1% | 14 | $104.04 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 27 | $91.29 |
| 87147 | <1% | 14 | $90.19 | |
| 87324 | <1% | 12 | $65.42 | |
| G0008 | Administration of influenza virus vaccine | <1% | 73 | $41.40 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 44 | $27.73 |
| 82746 | <1% | 12 | $17.36 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 61 | $9.83 |
| 84156 | <1% | 13 | $1.58 | |
| Q0222 | Injection, bebtelovimab, 175 mg | 0% | 32 | $0.00 |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 25 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 40 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialKHALEGHI, TRISHA (SVP MARKET CEO)
| Provider | Location | Paid |
|---|---|---|
| Sharp Memorial Hospital | San Diego, CA | $2.42M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.